Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
| 대상 질환 | ALS |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Shionogi |
| 상태 | 조기 종료 |
| 참여자 수 | 384 명 |
| 중재(약물) | MT-1186 |
| 시작일 | 2020년 11월 13일 |
| 완료일 | 2023년 9월 29일 |
| 결과 공개일 | 2025년 3월 27일 |
요약
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:
CAFS Score at Week 48
| Edaravone 105 mg (Once Daily) | 187.2 Units on a scale |
|---|---|
| Edaravone 105mg (2 Weeks On/Off ) | 184.2 Units on a scale |
| p-value | 0.777 |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Ed — Shionogi
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
- Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi